Additionally, both MMP9 and apoE4 have been implicated in early AD pathology before the onset of cognitive impairment [55–59], so therapeutic approaches targeting MMP9 may require early administration to see the greatest benefits. Here, MMP9 is linked to Cognitive impairment.